Roche Sees Cancer Combos Start To Deliver

Roche presented a strong second quarter and was able to highlight a positive debut of Tecentriq, its PD-L1 antagonist, which brought the Swiss group into the lauded programed-death checkpoint inhibitor field.

Schwan_Severin_1200x675
CEO Severin Schwan • Source: Roche

Roche said group sales increased 5% to CHF25bn in the six months to June 30, slightly ahead of expectations. Net income rose by 3% at constant currencies to CHF5.5bn. Pharmaceutical sales were up by 4% to CHF19.5bn, driven by oncology and immunology drugs.

Tecentriq (atezolizumab), which was approved by the FDA in May 2016 for bladder cancer, had revenues of CHF19m "in a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip